tbuckley/cabot-search huggingface dataset:
Early Pembrolizumab Ups TNBC Responses
Journal: Cancer Discovery (2019)

Abstract Pembrolizumab plus chemotherapy may be an effective neoadjuvant therapy in patients with early-stage triple-negative breast cancer: In an interim analysis of the phase III KEYNOTE-522 trial, patients treated with the combination had a higher pathologic complete response rate and trended toward better event-free survival than those who received chemotherapy alone.
Results of High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.
Authors: Kenneth A. Ault, Delvyn C. Case, Marjorie A. Boyd, Thomas J. Ervin, Frederick R. Aronson, Kurt S. Ebrahim, Jaquelyn A. Hedlund
Journal: Blood (2004)
THE CURE OF TABES DORSALIS.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the NIH: Rapid and convenient access to the medical literature
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Radioisotopes in malignancies in children. Use in the study of involvement by primary and metastatic processes in brain and liver
Authors: M. Tefft
Journal: JAMA (1969)

Of 1,500 children undergoing brain scanning, approximately 90% with low-grade cerebellar astrocytomas and 45% with medulloblastoma will have positive scans. In the supratentorial region, 85% to 90% of patients with highly malignant gliomas (grade 3-4), 15% to 20% of patients with low-grade gliomas (grade 1-2), 65% with optic glioma, and 30% with symptoms or signs, or both, of infiltration by acute leukemia, will have positive scans. Among 800 children having liver scans, primary lesions (hepatoma) were found in 100% of proven cases; and metastatic foci, in approximately 85% of those with proven liver metastases. The liver scan was useful in outlining liver volume for radiotherapeutic management. At routine liver scanning, a spleen scan was obtained to outline splenic cysts in 100% of children examined. With newer isotopes, scanning is applicable now as a routine method of survey in children.
NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with positive axillary (PAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC).
Authors: Eleftherios P. Mamounas, Hanna Bandos, Julia R. White, Thomas B. Julian, Atif J. Khan, Simona Flora Shaitelman, Mylin Ann Torres, Frank Vicini, Patricia A. Ganz, Susan Ann McCloskey, Soonmyung Paik, Nilendu Gupta, X. Allen Li, Dominic J. DiCostanzo, Walter John Curran, Norman Wolmark
Journal: Journal of Clinical Oncology (2018)

TPS601 Background: This phase III post-NC trial evaluates if CWRNRT post-Mx or whole breast irradiation (WBI) with RNRT after BCS significantly reduces the IBCR-FI rate in pts with PAx nodes that are negative after NC. Secondary aims are OS, LRR-FI, DR-FI, DFS-DCIS, second primary cancer, and comparison of RT effect on cosmesis in reconstructed Mx pts. Correlative science examines RT effect by tumor subtype, molecular outcome predictors for residual disease pts, and predictors for the degree of reduction in locoregional recurrence. Methods: Clinical T1-3, N1 IBC PAx nodes (FNA or core needle biopsy) pts complete ≥8 weeks of NC (anthracycline and/or taxane). HER2+ pts receive anti-HER2 therapy. Following NC, BCS or Mx, sentinel node biopsy (≥2 nodes) and/or Ax dissection with histologically negative nodes is performed. ER/PR and HER-2neu status before NC is required. Pts receive appropriate adjuvant systemic therapy. Radiation credentialing with a facility questionnaire/case benchmark is required. Random assignment for Mx pts is to no CWRNRT or CWRNRT and for BCS pts to WBI or WBI+RNRT. Statistics: 1636 pts to be enrolled over 5 yrs (definitive analysis at 7.5 yrs). Study is powered at 80% to test that RT reduces the annual hazard rate of events for IBCR-FI by 35% for an absolute risk reduction of 4.6% (5-yr cumulative rate). Intent-to-treat analysis with 3 interim analyses (43, 86, and 129 events) and a 4th/final analysis at 172 events. Pt-reported outcomes focusing on RT effect will be provided by 736 pts before random assignment and at 3, 6, 12, and 24 mos. Accrual as of 1-23-18 is 848 (51.83%). Contacts: Protocol: CTSU member website https://www.ctsu.org. Questions: NRG Oncology Pgh Clin Coord Dpt: 1-800-477-7227 or ccd@nsabp.org. Pt entry: OPEN at https://open.ctsu.org or the OPEN tab on CTSU member website. Support: U10 CA-2166; -180868, -180822; 189867; Elekta Clinical trial information: NCT01872975.
Alcohol's threat to liver transplant recipients may be overstated, suggests retrospective study
Authors: P. Cotton
Journal: JAMA (1994)

DISCRIMINATION against alcoholics in liver transplant programs may be unwarranted, or at least excessive. Most transplant programs exclude alcoholics who cannot convince clinicians that they will stay on the wagon. This policy is based on the theory that relapse in alcohol addiction is voluntary behavior, and that alcohol consumption damages the grafted liver, leading to a willful waste of a scarce resource. Fully 80% of liver transplant programs won't even consider current heavy drinkers; 23.9% won't take patients who abused alcohol in the past 6 months, and 58.7% say drinking in the past 6 months is a "relative" contraindication (<i>Psychosomatics</i>. 1993;34:314-323). <h3>Rejection and Death Not Higher</h3> However, alcoholics who do start drinking again after transplantation do not have increased rates of histological abnormalities, graft rejection, or death, according to a retrospective study conducted at the University of Michigan Medical School, Ann Arbor. All patients who had a history of alcohol
Food and Drug Administration
Authors: Linda R Horton
Journal: BMJ (2007)

Incident reporting should ideally communicate all information relevant to patient safety.Local incident reporting systems in hospitals typically use an incident form that comprises basic clinical details and a brief description of the incident.Such systems are ideally used as part of an overall safety and quality improvement strategy, but in practice they may be dominated by managing claims and complaints. 1 Specialty reporting systems 2 and large scale systems, such as that of the UK National Patient Safety Agency (www.npsa.nhs.uk/),allow wider dissemina-
THE MODERN CLASSIFICATION OF THE SO-CALLED "BLASTOMYCOSES". P. Redaelli. (Giorn. Ital. di Derm. e Sifilo, 1935, p. 253.)
Authors: R. C. L.
Journal: British Journal of Dermatology (1935)

Journal Article THE MODERN CLASSIFICATION OF THE SO‐CALLED "BLASTOMYCOSES". P. Redaelli. (Giorn. Ital. di Derm. e Sifilo, 1935, p. 253.) Get access R. C. L. R. C. L. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 47, Issue 11, 1 November 1935, Page 489, https://doi.org/10.1111/j.1365-2133.1935.tb10233.x Published: 01 November 1935
Does Cardioplegia Type Affect Outcome and Survival in Patients With Advanced Left Ventricular Dysfunction?
Authors: Joseph E. Flack, James R. Cook, Susanne J. May, Stanley Lemeshow, Richard M. Engelman, John A. Rousou, David W. Deaton
Journal: Circulation (2000)

Background —There is controversy regarding which cardioplegic solution, temperature, and route of administration provides superior protection. The CABG Patch Trial enrolled a high-risk group of coronary artery disease patients with an ejection fraction of &lt;36%. Thus, they constitute an ideal group to benefit most from optimal cardioplegic protection. Methods and Results —All patients randomized into the trial were compared with respect to the use of blood and crystalloid cardioplegia. In addition, a questionnaire was sent to surgeons requesting blood cardioplegic temperature and route. Patients receiving crystalloid cardioplegia versus those receiving blood cardioplegia were found to have significantly more operative deaths (2% versus 0.3%, P =0.02), postoperative myocardial infarctions (10% versus 2%, P &lt;0.001), shock (13% versus 7%, P =0.013), and postoperative conduction defects (21.6% versus 12.4%, P =0.001). Despite this, early death (6% crystalloid versus 4% blood cardioplegia) and late death (24% crystalloid versus 21% blood cardioplegia) statistics were not significantly different. Patients receiving normothermic blood had less postoperative right ventricular dysfunction (10%) than did patients receiving cold blood (25%) or cold blood with warm reperfusion (30%) ( P =0.004). There was no significant difference in early or late death. Finally, patients who received combined antegrade and retrograde cardioplegia had significantly less inotrope use (71% versus 84%, P =0.002), right ventricular dysfunction (23% versus 41%, P =0.001), and postoperative balloon pump use (12% versus 19%, P =0.02) than did those who received antegrade cardioplegia. There was no difference in survival. Conclusions —Blood cardioplegia and combined antegrade and retrograde cardioplegia are superior to crystalloid and antegrade cardioplegia alone for postoperative morbidity. Despite this, there is no significant difference in early or late survival.
AN EVACUATING ATTACHMENT FOR THE CYSTOSCOPE
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Influenza immunization changes for elderly?
Authors: D. E. Riesenberg
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopy/endoscopic ultrasound
Authors: P Grigoriev, E Antohin, A Yakovenko, E Yakovenko, I Suzdalova, N Yenice, C Zergegit, N Aksoy, K Kutoglu, A Zissimopoulos, I Kataitianos, E Tsaousides, A Karanassou, A Adreopoulos, Ch Papadogeorgopoulos, E Dracou, A Armonis, S Manolakopoulos, N Papadimitriou, P Gouma, A Avgerinos, A Balzano1, A Bove1, N Panza, M Bianco3, A Colao4, B Merola4, M Barenys, A Abad, V Romagosa, M Admetlla
Journal: Gut (1994)

Aim: To investigate the efficiency of combination of M1-selective receptor antagonist gastrozepine and triple therapy (Denol + amoxicillin + metranida- zole) in the treatment of Helicobacter pylori (HP) positive duodenal ulcer(DU) patients (pts) resistant to 8 weeks treatment of ranitidine 300 mg/d.Methods: 38 pts with endoscopically proven DU (diameter was not less than 5 mm) randomized into 2 groups receiving: Group A (n = 20) Gas- trozepine (100 mg/d for 2 weeks then 50 mg/d for 2 weeks) + De-nol (colloidal bismuth subcitrate) 480 mg/d for 4 weeks combined with amoxicillin 500 mg g. i. d. and metronidazole 250 mg g. i. d. for the first two weeks (triple ther- apy).Group B (n = 18) omeprazole 20 mg/d for 4 weeks and amoxicillin 500 mg g. i. d. for 2 weeks.The pts were rescoped 4 weeks, 6 and 12 months after the end of the treatment.HP was sought by histology and biopsy urase test.Eradication was defined as all tests negative at 4 weeks post treatment.Results are summarized below: Group Healing DU Eradication HP Relapse DU (%) (%) (%) A(n=20) 80 70 15 B (n = 18) 88.9 66.7 27.8Conclusion: There results indicate, that type of combined triple therapy with Gastrozepine is as effective as Omeprazole with amoxicillin in healing resistant DU, in HP eradication and in prevention of DU relapse.It is a good alternative in HP positive DU pts resistant to H2-bloker.
Blood
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Syphilis
Authors: G. Marshall Crawford
Journal: New England Journal of Medicine (1948)

Serologic ProblemsA diagnosis of syphilis made on purely serologic grounds is to be avoided if possible; nevertheless, the necessity of relying on serologic findings is all too often inescapable. A good example of a typical situation is a survey of 82,070 consecutively examined male maritime enrollees, aged sixteen to fifty-four years.42 Among this clinically healthy population, there were 783 with positive reactions to the Kahn standard serologic test for syphilis. In 47 per cent of these 783 men a diagnosis of syphilis was eventually made; weakly positive reactions proved to mean syphilis in only 20 per cent of this . . .
FGF-2 Stimulation of RANK Ligand Expression in Paget’s Disease of Bone
Authors: Kumaran Sundaram, Joseph Senn, Sambandam Yuvaraj, D. Sudhaker Rao, Sakamuri V. Reddy
Journal: Endocrine Reviews (2009)

ABSTRACT Receptor activator for nuclear factor-κB ligand (RANKL), a critical osteoclastogenic factor expressed in marrow stromal/preosteoblast cells is up-regulated in Paget’s disease of bone (PDB). We previously demonstrated that heat-shock factor-2 (HSF-2) is a downstream target of fibroblast growth factor-2 (FGF-2) signaling to induce RANKL expression in bone marrow stromal/preosteoblast cells. In this study, we identified a 2.5-fold increase in serum FGF-2 levels in patients (n = 8) with PDB compared with normal subjects (n = 10). We showed that HSF-2 co-immunoprecipitates with heat-shock protein-27 (HSP-27) and that FGF-2 stimulation significantly increased phospho-HSP-27 levels in marrow stromal cells. Confocal microscopy revealed HSF-2 colocalization with HSP-27 in unstimulated cells and HSF-2 nuclear translocation upon FGF-2 stimulation. We further show that FGF-2 stimulation significantly increased the levels of phosphorylated signal transducers and activators of the transcription (p-STAT-1) in these cells. Western blot analysis confirmed that small interfering RNA suppression of STAT-1 significantly decreased (3.2-fold) RANKL expression and promoter activity in FGF-2-stimulated cells. Chromatin immunoprecipitation assay revealed STAT-1 binding to a putative motif located far upstream (−8 kb) in the hRANKL gene promoter region. These results suggest STAT-1 is a downstream effector of FGF-2 signaling and that elevated levels of FGF-2 stimulates RANKL expression in PDB.
Patient characteristics at time of prostate cancer diagnosis in different races at an academic center serving a diverse population.
Authors: Tejas Suresh, Qi Gao, Mimi Kim, Sanjay Goel, Benjamin Adam Gartrell
Journal: Journal of Clinical Oncology (2016)

158 Background: In the United States, prostate cancer (PCa) incidence and death rate differ among racial groups. Non-Hispanic Blacks (NHB) have a higher incidence and death rate than non-Hispanic Whites (NHW), whereas incidence and death rate are slightly lower in Hispanics (H) than in NHW. We sought to compare the socioeconomic, demographic and baseline prognostic factors at PCa diagnosis among different races at a large, urban academic center serving a diverse population. Methods: Following institutional review board approval, the Montefiore Medical Center Cancer Registry was used to generate a comprehensive list of patients diagnosed with PCa 2004 to 2013. Clinical Looking Glass (a searchable database of patient information) and individual patient chart review were used to obtain data including age at diagnosis, socioeconomic score (SES), Gleason score, stage at diagnosis and PSA at diagnosis. Patients were classified by self-identified race as H, NHB or NHW. For categorical variables the chi-square test was used, whereas the ANOVA or the Kruskal-Wallis tests were employed for continuous variables. Results: During the specified period 2352 patients were diagnosed with PCa among which 778 were self-classified as H, 1046 as NHB, 486 as NHW and 42 as other (O). The mean age at diagnosis differed between these groups (H 63.2, NHB 63.4, NHW 67, O 63.0, p &lt; 0.0001). The proportion of men below the mean SES also differed between races (H 92.8%, NHB 91.3%, NHW 56.6%, O 75%, p &lt; 0.0001). Median PSA (ng/ml) at diagnosis was similar (H 8.0, NHB 8.4 NHW 7.2, O 6.4, p = 0.0768) whereas Gleason score differed between racial groups (Gleason ≤ 6: H 42.8%, NHB 39.1%, NHW 52.2%, O 50%; Gleason 8-10: H 15.8%, NHB 17.6%, NHW 14.3%, O 16.7%, p = 0.0005). The proportion of men with metastatic disease at diagnosis also differed significantly in these groups (H 7.5%, NHB 9.0%, NHW 4.3%, O 9.5%, p = 0.0139). Conclusions: At our center, in patients with newly diagnosed PCa, there are significant differences among racial groups. These include age at diagnosis, SES, Gleason score and proportion with metastatic disease. Such differences at diagnosis suggest that minority patients are at risk for inferior PCa outcomes.